Evaluation of Metformin impact on the downstaging of rectal cancer patients undergoing neo-adjuvant chemo-radiotherapy
Phase 3
Recruiting
- Conditions
- Rectal Cancer.Malignant carcinoid tumor of the rectumC7A.026
- Registration Number
- IRCT20170728035349N2
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Having rectal cancer and being a candidate for neo-adjuvant chemo-radiotherapy
Age over 20 and under 70 years
Exclusion Criteria
Previous history of liver or kidney disease
Previous history of moderate to severe heart failure
History of MI during the last 6 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Down Staging in Rectal Cancer Patients in Neo-adjuvant and Metformin Concomitant Recipients. Timepoint: MRI and biopsy of the rectal mucosa to determine the stage of the tumor and compare with similar cases performed at the beginning of the study, Follow-up of patients in both groups at intervals of 1, 3 and 6 months in terms of possible treatment complications, non-recurrent survival, cancer-specific survival and overall survival. Method of measurement: MRI.
- Secondary Outcome Measures
Name Time Method